Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.
Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.
LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.
Source: Read Full Article
Lates News:
-
HP Drops 5% In Pre-market On Slashing Annual Outlook Below View
-
BTC Developer Says: 2024 Bitcoin Core Update to Disrupt Ordinals and BRC-20 Tokens
-
How Much Bitcoin Can You Mine in a Day?
-
Crypto Analyst: ‘This Is Historically the Optimal Time To Allocate to Bitcoin’
-
$BTC: Former SEC Enforcement Attorney Explains Why “Bitcoin’s Price Is Rising”